The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors
Open accessAbstract
Advances in our understanding of the biological basis and molecular characteristics of ependymal tumors since the latest iteration of the World Health Organization (WHO) classification of CNS tumors (2016) have prompted the cIMPACT‐NOW group to recommend a new classification. Separation of ependymal tumors by anatomic site is an important principle of the new classification and was prompted by methylome profiling data to indicate that molecular groups of ependymal tumors in the posterior fossa and supratentorial and spinal compartments are distinct. Common recurrent genetic or epigenetic alterations found in tumors belonging to the main molecular groups have been used to define tumor types at intracranial sites; C11orf95 and YAP1 fusion genes for supratentorial tumors and two types of posterior fossa ependymoma defined by methylation group, PFA and PFB. A recently described type of aggressive spinal ependymoma with MYCN amplification has also been included. Myxopapillary ependymoma and subependymoma have been retained as histopathologically defined tumor types, but the classification has dropped the distinction between classic and anaplastic ependymoma. While the cIMPACT‐NOW group considered that data to inform assignment of grade to molecularly defined ependymomas are insufficiently mature, it recommends assigning WHO grade 2 to myxopapillary ependymoma and allows grade 2 or grade 3 to be assigned to ependymomas not defined by molecular status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
Self-citationDNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Self-citationPajtler, K. W., Witt, H., Sill, M., Jones, D. T. W., Hovestadt, V., Kratochwil, F., Wani, K., Tatevossian, R., Punchihewa, C., Johann, P., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.002 · Cited by 1,225
Self-citationNew Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm, D., Orr, B. A., Toprak, U. H., Hovestadt, V., Jones, D. T. W., Capper, D., Sill, M., Buchhalter, I., Northcott, P. A., Leis, I., et al. (2016) · Cell · doi:10.1016/j.cell.2016.01.015 · Cited by 975
Self-citationC11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma
Parker, M., Mohankumar, K. M., Punchihewa, C., Weinlich, R., Dalton, J. D., Li, Y., Lee, R., Tatevossian, R. G., Phoenix, T. N., Thiruvenkatam, R., et al. (2014) · Nature · doi:10.1038/nature13109 · Cited by 670
Self-citationEpigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Self-citationLouis, D. N., Perry, A., Burger, P., Ellison, D. W., Reifenberger, G., von Deimling, A., Aldape, K., Brat, D., Collins, V. P., Eberhart, C., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12171 · Cited by 580
Self-citationDelineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
Witt, H., Mack, S. C., Ryzhova, M., Bender, S., Sill, M., Isserlin, R., Benner, A., Hielscher, T., Milde, T., Remke, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.007 · Cited by 559
Self-citationEllison, D. W., Kocak, M., Figarella-Branger, D., Felice, G., Catherine, G., Pietsch, T., Frappaz, D., Massimino, M., Grill, J., Boyett, J. M., et al. (2011) · Journal of Negative Results in BioMedicine · doi:10.1186/1477-5751-10-7 · Cited by 308
Self-citationMolecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., Hübner, J.-M., Ramaswamy, V., Jia, S., Dalton, J. D., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1877-0 · Cited by 262
Self-citation
Cited by
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Self-citationPrimary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Self-citationGritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022) · Acta Neurochirurgica · doi:10.1007/s00701-022-05301-y · Cited by 303
Metadata
- Authors
- Ellison, D. W., Aldape, K. D., Capper, D., Fouladi, M., Gilbert, M. R., Gilbertson, R. J., Hawkins, C., Merchant, T. E., Pajtler, K., Venneti, S., & Louis, D. N.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2020-06-23
- Volume
- 30
- Issue
- 5
- Pages
- 863-866
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W3034140733
- Cited by
- 278
- References
- 20
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors. https://app.cochat.ai/papers/10.1111/bpa.12866
- The paper
- Ellison, D. W., Aldape, K. D., Capper, D., Fouladi, M., Gilbert, M. R., Gilbertson, R. J., Hawkins, C., Merchant, T. E., Pajtler, K., Venneti, S., & Louis, D. N. (2020). cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology. https://doi.org/10.1111/bpa.12866
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.